Latest Breaking News On - Drug resistance company - Page 1 : comparemela.com

The trial’s primary endpoint was achieved, establishing the maximum tolerated dose of SCO-101 in combination with the standard chemotherapies gemcitabine and nab-paclitaxel in patients with. | March 31, 2023

Johnny stilouAlfredo zurloCancer drug resistance companyScandion oncologyChief medical officerDrug resistance companyNasdaq first north growth market swedenHamnen corporate financeNasdaq first north growthScandion oncologyas stock exchangePress releaseAtients scol dk0061031895